Next 10 |
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Marinus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Marinus stock or options between March 17, 2021 and May 7, 2024 and would like to discuss your legal...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Marinus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Marinus stock or options between March 17, 2021 and May 7, 2024 and would like to discuss your legal...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Marinus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Marinus stock or options between March 17, 2021 and May 7, 2024 and would like to discuss your legal...
NEW YORK, NY / ACCESSWIRE / July 10, 2024 / Bernstein Liebhard LLP: Do you, or did you, own shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)? Did you purchase your shares between March 17, 2021 and May 7, 2024, inclusive? Did you lose money in your investment in Marinus Pha...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Marinus stock or options between March 17, 2021 and May 7...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Marinus stock or options between March 17, 2021 and May 7...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Marinus stock or options between March 17, 2021 and May 7...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Marinus stock or options between March 17, 2021 and May 7...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...